A comprehensive review of patient-reported outcomes in metabolic dysfunction-associated steatotic liver disease
Metabolism and Target Organ Damage · 20.11.2024 · 4 (4)
DOI: 10.20517/mtod.2024.70 ↗Kurz gefasst
Fachartikel in der Zeitschrift Metabolism and Target Organ Damage, online erschienen am 20.11.2024. Verfasst von Aybuke Sapmaz und 3 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 75 Literaturangaben.
Abstract (Originalsprache)
The global prevalence of obesity and type 2 diabetes has increased, contributing to an increased worldwide prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD). Currently, one in three adults is affected by MASLD and/or its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), making this liver disease a significant public health challenge. Along with MASH-related cirrhosis, these conditions are poised to become the leading causes of chronic liver disease and liver transplants in the near future. Given the growing burden of MASLD and MASH, it is crucial to understand their impact from the patients’ perspective. One way to do this is by assessing patient-reported outcomes (PROs), including health-related quality of life (HRQL). HRQL can be assessed using generic instruments like the short form 36 version (SF-36) and the European quality of life-5 dimensions questionnaire (EQ-5D), or disease-specific tools such as the chronic liver disease questionnaire for nonalcoholic steatohepatitis (CLDQ-NASH). Given the limitations of each instrument, the best approach generally involves using both generic and disease-specific instruments. Evidence indicates that HRQL scores are significantly lower in individuals with MASLD, especially in areas assessing physical activity and the ability to perform daily living tasks. Fatigue and impaired work productivity are also important PROs for those with MASLD/MASH. These decrements in PROs worsen with disease progression but appear to improve with disease regression, including improvements linked to treatment. In this context, measuring PROs enhances the assessment of other patient-centric outcomes and provides insights for the healthcare community to develop interventions that could improve both clinical and humanistic outcomes for individuals living with MASLD/MASH.
Zitieren
APA
Sapmaz, A., Paik, A., Henry, L., & Younossi, Z. M. (2024). A comprehensive review of patient-reported outcomes in metabolic dysfunction-associated steatotic liver disease. Metabolism and Target Organ Damage, 4(4). https://doi.org/10.20517/mtod.2024.70
Vancouver
Sapmaz A, Paik A, Henry L, Younossi ZM. A comprehensive review of patient-reported outcomes in metabolic dysfunction-associated steatotic liver disease. Metabolism and Target Organ Damage. 2024;4(4). doi:10.20517/mtod.2024.70
BibTeX
@article{Sapmaz2024,
author = {Sapmaz, Aybuke and Paik, Annette and Henry, Linda and Younossi, Zobair M.},
title = {A comprehensive review of patient-reported outcomes in metabolic dysfunction-associated steatotic liver disease},
journal = {Metabolism and Target Organ Damage},
year = {2024},
volume = {4},
number = {4},
doi = {10.20517/mtod.2024.70}
}
EUVIMED